Funding
Ecole Polytechnique Fédérale de Lausanne (EPFL) spin-out Biocartis SA has raised €10 million in its first funding round. The money will be used for the further development of its integrated molecular and immunodiagnostics platform.
The deal was led by Aescap Venture of Amsterdam, with Biovest, KBC Private Equity of Belgium and Advent Venture Partners UK. Existing shareholder Benaruca of Luxemburg followed on.
Dinko Valerio for Aescap Venture, Rudi Mariën for Biovest, Ruth Devenyns for KBC Private Equity, Raj Parekh for Advent Venture Partners, Peter Verhaeghe for Benaruca and Rudi Pauwels will constitute the board of directors of Biocartis.
Biocartis has developed and licensed a series of technologies to build a widely applicable diagnostics platform for low- to highly-multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules.
The company will use the proceeds to develop a commercial version of its proprietary platform and first prototype assays.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.